Activation of FAK and ERK1/2 Involves in Lenvatinib Resistance to Human Hepatocellular Carcinoma Cell Line PLC/PRF/5 in Hypoxia

○Masanori Takahashi

[28P02-L008] Activation of FAK and ERK1/2 Involves in Lenvatinib Resistance to Human Hepatocellular Carcinoma Cell Line PLC/PRF/5 in Hypoxia

○Masanori Takahashi^1,2, Kouji Okada^1,2, Kensuke Usui^1,2, Ryusuke Ouchi^1,2, Hiroyuki Suzuki^1,2, Taisuke Konno^1,2, Hitoshi Nakamura¹, Takayuki Kogure³, Mari Satoh³, Kennichi Satoh³, Yoshiteru Watanabe^1,2, Yuriko Murai¹ (1. Pharm. Sci., Tohoku Med. and Pharm. Univ., 2. Tohoku Med. and Pharm. Univ. Hosp., Pharmacy, 3. Tohoku Med. and Pharm. Univ. Hosp., Gastroenterology)

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.

Presentation information

[28P02] 薬理学③

[28P02-L008] Activation of FAK and ERK1/2 Involves in Lenvatinib Resistance to Human Hepatocellular Carcinoma Cell Line PLC/PRF/5 in Hypoxia

Password